The Amarin (AMRN) saga is not over yet. Following a somewhat dramatic couple of weeks after the release of the biopharmaceutical’s drug, Vascepa, analysts …
Blogger Christiana Friedman says the FDA decision for Amarin’s (AMRN) drug Vascepa might not be the make or break for the company. In …
H.C.
Amarin Corporation (AMRN) released a firecracker presentation Saturday at Chicago’s American Heart Association conference and investors can’t seem to stop talking about it. …
Amarin (AMRN) stock has risen and dipped after varying responses from investors who were tuned into data reports from the biotech’s cardio-vascular REDUCE-It …
Amarin (AMRN) stock is on a nosedive today, falling over 20%, after the Irish biopharma showed updated results from a cardiovascular study called …
Amarin (AMRN) investors should expect material news on November 10, as that’s when the fish oil drug maker plans to release additional details from …
Cantor analyst Louise Chen was out pounding the table on shares of Amarin (AMRN) Thursday, reiterating an Overweight rating with a price target of $35, which …
Amarin (AMRN) shocked Wall Street last month. As a brief recap, the fish oil drug maker released promising data from a highly anticipated study of …
Can you feel the ground moving beneath your feet? Amarin (AMRN) share price has jumped nearly seven-folds in value over the past 2 …